In adult patients with recurrent Clostridium difficile infection, Fecal microbiota transplantation (FMT) performed better than Vancomycin alone or Fidaxomicin alone.
in this open-labeled randomized trial published in the journal Gastroenterology, Hvas et al randomized 64 adults in one of the following three groups:
1- FMT by colonoscopy or nasojejunal tube, after 4–10 days of vancomycin (125 mg 4 times daily),
2- Fidaxomicin 200 mg twice daily for 10 days
3- Vancomycin 125 mg 4 times daily for 10 days.
The primary outcome was combined clinical resolution and a negative result from a polymerase chain reaction test for Clostridium difficile toxin 8 weeks after the treatment.
The primary outcome was met in 71% of FMT group, 33% in the Vancomycin group and 19% in Fidaxomicin group.
The future is bright for fecal transplantation in Clostridium difficile infection
Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection
Christian Lodberg Hvas,1 Simon Mark Dahl Jørgensen,1 Søren Peter Jørgensen,1 Merete Storgaard,2 Lars Lemming,3 Mette Mejlby Hansen,1 Christian Erikstrup,4 and Jens Frederik Dahlerup1
1 Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; 2 Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; 3 Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark; and 4 Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
A SYSTEMATIC REVIEW OF DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRES IN CHILDREN AND ADULTS WITH CELIAC DISEASE.
Pegah Amir Yazdani, Pouneh Amir Yazdani, Martha Dirks, Prévost Jantchou.
ESPGHAN 2019
TISSUE-TRANSGLUTAMINASE ANTIBODY HIGHER THAN 10 TIMES THE NORMAL VALUE IS A RELIABLE PREDICTIVE TEST OF VILLOUS ATROPHY IN PATIENTS WITH SUSPICION OF CELIAC DISEASE
T. Nguyen, O.V. Portolese, N. Patey, D. Dal Soglio, L. Oligny, M. Dirks, P. Jantchou
ESPGHAN2019
Worldwide Survey Of Current Digestive Endoscopy Practice in Children
Prevost Jantchou, Kiana Tchan, Noemie Laverdure, Lara Hart, Jennifer Ao, Mallory Chavannes
ESPGHAN2019
Cette année le 50 congrès du Digestive Disease Week [DDW] se tiendra à San Diego, Californie.
Voici nos abstracts qui seront présentés.
1- THE FACTORS ASSOCIATED WITH THE LEVELS OF PHYSICAL ACTIVITY IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE
Xin Yu Yang, Si Yuan Geng, Caitlyn Kanters, Sabrina Madagh, Lina Belmesk, Fella Chennou, Prevost Jantchou
Presentation Number: Mo1771
2- MEASUREMENT OF STRESS AND ANXIETY AND THE ASSOCIATED FACTORS IN PEDIATRIC GASTROENTEROLOGY PATIENTS
Matthew Abdaem, Si Yuan Geng, Shiyin Lao, Prevost Jantchou.
Presentation Number: Tu1602
3- TRENDS IN TNF-ALPHA INHIBITOR UTILIZATION IN CHILDREN WITH IBD DURING THE LAST 10 YEARS: 2009-2018
R. Iratni, F. Karkri , C. Deslandres, P. Jantchou
Presentation Number: Sa1759
Le saviez vous…
Ou
Ou
Parents: Attention certains jouets peuvent être dangereux pour les enfants surtout les jeunes enfants.
Enfants: Si vous voulez manger du poisson demander plutôt à maman de vous en cuisiner. Les poissons en éponge ne sont pas très nourrissants.
Abstracts présentés au congrès CDDW 2019 à Banff, AB :
http://cddw.cag-acg.org/sites/cag-acg/en/cddw
TITLE: RELATION BETWEEN VITAMIN D STATUS AND IBD RELATED HOSPITALIZATION IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE TREATED WITH IMMUNOSUPPRESSANT OR BIOLOGICAL AGENTS
AUTHORS (FIRST NAME, LAST NAME): Fella
INSTITUTIONS (ALL): 1. CHU SainteJustine, Department of Pediatrics, Unit of Gastroenterology, Montreal, QC, Canada. 2 Research center of CHU SainteJustine, Montreal, QC, Canada.
TISSUE-TRANSGLUTAMINASE ANTIBODY HIGHER THAN 10 TIMES THE NORMAL VALUE IS A RELIABLE PREDICTIVE TEST OF VILLOUS ATROPHY IN PATIENTS WITH SUSPICION OF CELIAC DISEASE
T. Nguyen 2 , O.V. Portolese 1 , N. Patey 4 , D. Dal Soglio 4 , L. Oligny 4 , M. Dirks 3 , P. Jantchou 1,3
TRENDS IN THE CLINICAL PRESENTATION OF CELIAC DISEASE AT DIAGNOSIS IN CHILDREN IN QUEBEC
O.V. Portolese
IS IBD-CONTROL QUESTIONNAIRE A RELIABLE PATIENT REPORTED OUTCOME IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE?
L. Belmesk
TRENDS IN TNF-ALPHA INHIBITOR UTILIZATION IN CHILDREN WITH IBD DURING THE LAST 10 YEARS: 2009-2018
R. Iratni 1 , F. Karkri 1 , C. Deslandres 1,2 , P. Jantchou 1,2,3